{"id": "article-26562_0", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Continuing Education Activity", "content": "Intraductal papillary mucinous neoplasms (IPMNs) are cystic neoplasms of the pancreas that grow within the pancreatic ducts and produce mucin. They have the potential to become malignant, so it is important to diagnose and manage them early and appropriately. This activity reviews the evaluation and management of intraductal papillary mucinous neoplasms and highlights the role of the interprofessional team in the care of affected patients.", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Continuing Education Activity. Intraductal papillary mucinous neoplasms (IPMNs) are cystic neoplasms of the pancreas that grow within the pancreatic ducts and produce mucin. They have the potential to become malignant, so it is important to diagnose and manage them early and appropriately. This activity reviews the evaluation and management of intraductal papillary mucinous neoplasms and highlights the role of the interprofessional team in the care of affected patients."}
{"id": "article-26562_1", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Continuing Education Activity", "content": "Objectives: Review the epidemiology of intraductal papillary mucinous neoplasms. Identify the types of intraductal papillary mucinous neoplasms. Summarize the diagnosis and management of intraductal papillary mucinous neoplasms. Explain the importance of collaboration and coordination among the interprofessional team to optimize outcomes for patients with intraductal papillary mucinous neoplasms. Access free multiple choice questions on this topic.", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Continuing Education Activity. Objectives: Review the epidemiology of intraductal papillary mucinous neoplasms. Identify the types of intraductal papillary mucinous neoplasms. Summarize the diagnosis and management of intraductal papillary mucinous neoplasms. Explain the importance of collaboration and coordination among the interprofessional team to optimize outcomes for patients with intraductal papillary mucinous neoplasms. Access free multiple choice questions on this topic."}
{"id": "article-26562_2", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Introduction", "content": "Intraductal papillary mucinous neoplasms\u00a0(IPMN) are\u00a0cystic neoplasms\u00a0of the pancreas that grow\u00a0within the pancreatic ducts and produce\u00a0mucin. They have the potential to become malignant, for that reason; diagnostic criteria have been published to identify which\u00a0patients will require\u00a0surgical resection. The criteria usually involve anatomic identification based on imaging\u00a0including the size of the cyst, the presence of a nodule, architectural changes, obstruction of the main duct, and presence of symptoms. [1] [2]", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Introduction. Intraductal papillary mucinous neoplasms\u00a0(IPMN) are\u00a0cystic neoplasms\u00a0of the pancreas that grow\u00a0within the pancreatic ducts and produce\u00a0mucin. They have the potential to become malignant, for that reason; diagnostic criteria have been published to identify which\u00a0patients will require\u00a0surgical resection. The criteria usually involve anatomic identification based on imaging\u00a0including the size of the cyst, the presence of a nodule, architectural changes, obstruction of the main duct, and presence of symptoms. [1] [2]"}
{"id": "article-26562_3", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Etiology", "content": "The risk factors of IPMNs are not clear. A few\u00a0conditions have been identified as possible risk factors for the development of IPMNs and\u00a0include diabetes (especially patients on insulin), chronic pancreatitis, and a family history of pancreatic ductal adenocarcinoma. [3] Smoking is an identified risk factor for pancreatic cancer [1] and has been associated with IPMNs as well. [4]", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Etiology. The risk factors of IPMNs are not clear. A few\u00a0conditions have been identified as possible risk factors for the development of IPMNs and\u00a0include diabetes (especially patients on insulin), chronic pancreatitis, and a family history of pancreatic ductal adenocarcinoma. [3] Smoking is an identified risk factor for pancreatic cancer [1] and has been associated with IPMNs as well. [4]"}
{"id": "article-26562_4", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Epidemiology", "content": "The true incidence of IPMNs\u00a0is unknown as most of them\u00a0are small and asymptomatic. Studies that evaluated cross-sectional images of patients without a history of pancreatic lesions\u00a0have shown that approximately 2.6 - 13.5% of adults have pancreatic cysts and the incidence\u00a0correlated with increasing age. [5] [6] The age of presentation is typically between the 5th and 7th decades. [7]", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Epidemiology. The true incidence of IPMNs\u00a0is unknown as most of them\u00a0are small and asymptomatic. Studies that evaluated cross-sectional images of patients without a history of pancreatic lesions\u00a0have shown that approximately 2.6 - 13.5% of adults have pancreatic cysts and the incidence\u00a0correlated with increasing age. [5] [6] The age of presentation is typically between the 5th and 7th decades. [7]"}
{"id": "article-26562_5", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Pathophysiology", "content": "IPMNs are thought to progress from benign neoplasms to invasive cancers through DNA damage/mutation. The damaged DNA loses protective factors and undergoes malignant degeneration leading to uncontrolled growth and convalescence.\u00a0KRAS and/or\u00a0GNAS mutations have been identified in IPMNs. [8] IPMNs can involve the\u00a0main pancreatic duct, a\u00a0branch duct or sometimes it can involve both and is considered a mixed duct\u00a0type. In all cases of main branch duct type involvement, surgical resection is recommended. Branch duct-type cases may be observed. Branch duct type IPMNs are generally believed to carry less risk of malignancy compared to main duct IPMNs [9] .", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Pathophysiology. IPMNs are thought to progress from benign neoplasms to invasive cancers through DNA damage/mutation. The damaged DNA loses protective factors and undergoes malignant degeneration leading to uncontrolled growth and convalescence.\u00a0KRAS and/or\u00a0GNAS mutations have been identified in IPMNs. [8] IPMNs can involve the\u00a0main pancreatic duct, a\u00a0branch duct or sometimes it can involve both and is considered a mixed duct\u00a0type. In all cases of main branch duct type involvement, surgical resection is recommended. Branch duct-type cases may be observed. Branch duct type IPMNs are generally believed to carry less risk of malignancy compared to main duct IPMNs [9] ."}
{"id": "article-26562_6", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Histopathology", "content": "IPMNs originate from stem cells of the epithelium of the pancreatic ducts which can differentiate into different phenotypes. They can have different subtypes based on their differentiation including\u00a0intestinal, pancreaticobiliary, oncocytic, and gastric types. [10] IPMNs usually progress from benign neoplasms to invasive cancers. This progression is graded based on the degree of dysplasia as\u00a0low-grade dysplasia (adenoma), moderate dysplasia (borderline), high-grade dysplasia (carcinoma in situ), and finally invasive carcinoma.\u00a0The progression from adenoma to carcinoma has been estimated to take 5-6 years to happen and it depends on the subtype of the IPMN. [10]", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Histopathology. IPMNs originate from stem cells of the epithelium of the pancreatic ducts which can differentiate into different phenotypes. They can have different subtypes based on their differentiation including\u00a0intestinal, pancreaticobiliary, oncocytic, and gastric types. [10] IPMNs usually progress from benign neoplasms to invasive cancers. This progression is graded based on the degree of dysplasia as\u00a0low-grade dysplasia (adenoma), moderate dysplasia (borderline), high-grade dysplasia (carcinoma in situ), and finally invasive carcinoma.\u00a0The progression from adenoma to carcinoma has been estimated to take 5-6 years to happen and it depends on the subtype of the IPMN. [10]"}
{"id": "article-26562_7", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Histopathology", "content": "When IPMNs become invasive, two different subtypes of carcinoma have been identified;\u00a0tubular type, which usually arises from the\u00a0pancreatobiliary IPMN and is morphologically similar to\u00a0pancreatic ductal adenocarcinoma and colloid (mucinous) type, which usually arises from intestinal IPMNs\u00a0and is\u00a0morphologically characterized by extensive pools of mucin similar to cancers of other exocrine glands. [10] Colloid carcinomas have a better prognosis than tubular carcinomas [11] .", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Histopathology. When IPMNs become invasive, two different subtypes of carcinoma have been identified;\u00a0tubular type, which usually arises from the\u00a0pancreatobiliary IPMN and is morphologically similar to\u00a0pancreatic ductal adenocarcinoma and colloid (mucinous) type, which usually arises from intestinal IPMNs\u00a0and is\u00a0morphologically characterized by extensive pools of mucin similar to cancers of other exocrine glands. [10] Colloid carcinomas have a better prognosis than tubular carcinomas [11] ."}
{"id": "article-26562_8", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- History and Physical", "content": "IPMNs\u00a0can come to clinical attention in a variety of different ways. They\u00a0can be asymptomatic and detected incidentally on imaging. However; when symptoms are present, they are usually nonspecific including\u00a0abdominal pain, back pain, nausea, vomiting, anorexia, and weight loss. They can also present with jaundice caused by obstruction of the bile ducts due to external compression or invasion\u00a0or\u00a0pancreatitis-like symptoms due to obstruction of the main pancreatic duct by mucin. [12]", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- History and Physical. IPMNs\u00a0can come to clinical attention in a variety of different ways. They\u00a0can be asymptomatic and detected incidentally on imaging. However; when symptoms are present, they are usually nonspecific including\u00a0abdominal pain, back pain, nausea, vomiting, anorexia, and weight loss. They can also present with jaundice caused by obstruction of the bile ducts due to external compression or invasion\u00a0or\u00a0pancreatitis-like symptoms due to obstruction of the main pancreatic duct by mucin. [12]"}
{"id": "article-26562_9", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Evaluation", "content": "The evaluation of IPMNs usually starts with imaging to evaluate the characteristics of the cyst, involvement of adjacent structures, and evidence of distant metastasis. Magnetic resonance imaging (MRI) with magnetic resonance cholangiopancreatography (MRCP) is first line. Computed tomography (CT) with pancreatic protocol is an alternative in patients whom MRIs are contraindicated. Endoscopic ultrasound (EUS) with fine-needle aspiration (FNA) should be used to assess cysts with malignant features, including large size, dilation of the main pancreatic duct, and/or presence of a solid component. Cystic fluid cytology can be assessed to look for atypical or malignant cells. Fluid markers, especially carcinoembryonic antigen (CEA), can help with the diagnosis as well. Cysts with a solid component and a dilated pancreatic duct or have malignant features on EUS and FNA should undergo surgical resection. Cysts with no concerning features should be monitored with MRIs. [13] [14]", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Evaluation. The evaluation of IPMNs usually starts with imaging to evaluate the characteristics of the cyst, involvement of adjacent structures, and evidence of distant metastasis. Magnetic resonance imaging (MRI) with magnetic resonance cholangiopancreatography (MRCP) is first line. Computed tomography (CT) with pancreatic protocol is an alternative in patients whom MRIs are contraindicated. Endoscopic ultrasound (EUS) with fine-needle aspiration (FNA) should be used to assess cysts with malignant features, including large size, dilation of the main pancreatic duct, and/or presence of a solid component. Cystic fluid cytology can be assessed to look for atypical or malignant cells. Fluid markers, especially carcinoembryonic antigen (CEA), can help with the diagnosis as well. Cysts with a solid component and a dilated pancreatic duct or have malignant features on EUS and FNA should undergo surgical resection. Cysts with no concerning features should be monitored with MRIs. [13] [14]"}
{"id": "article-26562_10", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Treatment / Management", "content": "Surgery is indicated in\u00a0patients with IPMNs and high-grade dysplasia or IPMNs that have progressed to invasive carcinoma. Surgery is recommended for all mucinous neoplasms and main duct neoplasms. In cases of branch duct cysts, observation may be elected. For patients with invasive ductal adenocarcinoma of the pancreas, postresection adjuvant therapy improves survival, even in patients with positive margins or involved lymph nodes. There is controversy as to the best adjuvant strategy.\u00a0Due to the significant morbidity and mortality associated with pancreaticoduodenectomy or distal pancreatectomy, the patient's and surgeon's decision to perform surgery should include\u00a0factors such as the patient's age and general health, the malignant risk of the lesion, and the suspicion for malignancy. Cysts not meeting the criteria for resection are typically followed with surveillance imaging [15] .", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Treatment / Management. Surgery is indicated in\u00a0patients with IPMNs and high-grade dysplasia or IPMNs that have progressed to invasive carcinoma. Surgery is recommended for all mucinous neoplasms and main duct neoplasms. In cases of branch duct cysts, observation may be elected. For patients with invasive ductal adenocarcinoma of the pancreas, postresection adjuvant therapy improves survival, even in patients with positive margins or involved lymph nodes. There is controversy as to the best adjuvant strategy.\u00a0Due to the significant morbidity and mortality associated with pancreaticoduodenectomy or distal pancreatectomy, the patient's and surgeon's decision to perform surgery should include\u00a0factors such as the patient's age and general health, the malignant risk of the lesion, and the suspicion for malignancy. Cysts not meeting the criteria for resection are typically followed with surveillance imaging [15] ."}
{"id": "article-26562_11", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Treatment / Management", "content": "If the main duct is greater than or equal to 1.5 cm, suitable patients should undergo surgical resection. If the whole duct is affected, then total pancreatectomy is the treatment of choice. If the head of the pancreas is affected, then Whipple's procedure (pancreaticoduodenectomy) is the operation of choice. If the tail of the pancreas is affected, then distal pancreatectomy plus or minus splenectomy may be warranted.", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Treatment / Management. If the main duct is greater than or equal to 1.5 cm, suitable patients should undergo surgical resection. If the whole duct is affected, then total pancreatectomy is the treatment of choice. If the head of the pancreas is affected, then Whipple's procedure (pancreaticoduodenectomy) is the operation of choice. If the tail of the pancreas is affected, then distal pancreatectomy plus or minus splenectomy may be warranted."}
{"id": "article-26562_12", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Differential Diagnosis", "content": "Differentials include pancreatic pseudocysts, serous cyst tumors, mucinous cyst neoplasms, and solid pseudopapillary neoplasms. Imaging including MRI,\u00a0MRCP, and\u00a0EUS with\u00a0FNA helps in differentiating IPMNs from other types of cysts.", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Differential Diagnosis. Differentials include pancreatic pseudocysts, serous cyst tumors, mucinous cyst neoplasms, and solid pseudopapillary neoplasms. Imaging including MRI,\u00a0MRCP, and\u00a0EUS with\u00a0FNA helps in differentiating IPMNs from other types of cysts."}
{"id": "article-26562_13", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Surgical Oncology", "content": "For operative technique, an upper midline incision is made, once, inside the abdomen, entrance to lesser sac is created with harmonic scalpel. Kocherization of the duodenum is performed. Once the pancreas is identified,\u00a0the tissue\u00a0is dissected\u00a0where the IPMN is involved.\u00a0As much as possible, the pancreatic parenchyma should be preserved to ameliorate the side effects of diabetes mellitus and exocrine insufficiency secondary to missing pancreatic\u00a0tissue. One trick for intraoperative surgery is to palpate the duct of the pancreas. If it feels dilated, then it has to be resected as it needs to be assumed that it is dilated due to increased mucin production (abnormal). Confirm negative margins with a frozen section\u00a0by sending to pathology.", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Surgical Oncology. For operative technique, an upper midline incision is made, once, inside the abdomen, entrance to lesser sac is created with harmonic scalpel. Kocherization of the duodenum is performed. Once the pancreas is identified,\u00a0the tissue\u00a0is dissected\u00a0where the IPMN is involved.\u00a0As much as possible, the pancreatic parenchyma should be preserved to ameliorate the side effects of diabetes mellitus and exocrine insufficiency secondary to missing pancreatic\u00a0tissue. One trick for intraoperative surgery is to palpate the duct of the pancreas. If it feels dilated, then it has to be resected as it needs to be assumed that it is dilated due to increased mucin production (abnormal). Confirm negative margins with a frozen section\u00a0by sending to pathology."}
{"id": "article-26562_14", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Radiation Oncology", "content": "There is no role for radiation in the management of\u00a0IPMNs.", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Radiation Oncology. There is no role for radiation in the management of\u00a0IPMNs."}
{"id": "article-26562_15", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Medical Oncology", "content": "There is no indication for chemotherapy for IPMN as it is considered a premalignant condition. Currently, surgery is the mainstay of\u00a0therapy. If an invasive cancer component is identified after surgery then the patient needs adjuvant chemotherapy. The chemotherapy would be gemcitabine, or gemcitabine plus capecitabine or modified FOLFIRINOX for 6 months", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Medical Oncology. There is no indication for chemotherapy for IPMN as it is considered a premalignant condition. Currently, surgery is the mainstay of\u00a0therapy. If an invasive cancer component is identified after surgery then the patient needs adjuvant chemotherapy. The chemotherapy would be gemcitabine, or gemcitabine plus capecitabine or modified FOLFIRINOX for 6 months"}
{"id": "article-26562_16", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Staging", "content": "Staging needs to be completed with CT of the chest, abdomen, and pelvis with intravenous contrast.", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Staging. Staging needs to be completed with CT of the chest, abdomen, and pelvis with intravenous contrast."}
{"id": "article-26562_17", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Prognosis", "content": "The 5-year survival for IPMNs\u00a0is about 45 to 50%\u00a0in comparison to pancreatic adenocarcinoma's 5-year survival of 8% [1] .", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Prognosis. The 5-year survival for IPMNs\u00a0is about 45 to 50%\u00a0in comparison to pancreatic adenocarcinoma's 5-year survival of 8% [1] ."}
{"id": "article-26562_18", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Complications", "content": "After surgery, complications such as bleeding, anastomotic leak, abscess, or death can occur. Pancreatic enterocutaneous fistulas are a dreaded complication of pancreatic surgery for which to be aware. Typically, these are treated with total parenteral nutrition (TPN), nothing by mouth, and drainage and possibly somatostatin analogs [16] .", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Complications. After surgery, complications such as bleeding, anastomotic leak, abscess, or death can occur. Pancreatic enterocutaneous fistulas are a dreaded complication of pancreatic surgery for which to be aware. Typically, these are treated with total parenteral nutrition (TPN), nothing by mouth, and drainage and possibly somatostatin analogs [16] ."}
{"id": "article-26562_19", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Postoperative and Rehabilitation Care", "content": "Early ambulation is recommended postoperatively. Drain placed at surgery should be removed after the oral diet is advanced and the patient tolerates a regular diet without an increase of drain output. If there is suspicion\u00a0of a pancreatic fistula, the fluid should be tested for amylase and lipase\u00a0which are expected to be elevated.", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Postoperative and Rehabilitation Care. Early ambulation is recommended postoperatively. Drain placed at surgery should be removed after the oral diet is advanced and the patient tolerates a regular diet without an increase of drain output. If there is suspicion\u00a0of a pancreatic fistula, the fluid should be tested for amylase and lipase\u00a0which are expected to be elevated."}
{"id": "article-26562_20", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Consultations", "content": "Physical therapy, occupational therapy, and nutritional consultations may be suggested.", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Consultations. Physical therapy, occupational therapy, and nutritional consultations may be suggested."}
{"id": "article-26562_21", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Deterrence and Patient Education", "content": "Patients need diabetes education. The patient needs to closely follow up with his primary care provider for diabetes management and prevention. Patients who smoke need to be given resources to quit smoking.", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Deterrence and Patient Education. Patients need diabetes education. The patient needs to closely follow up with his primary care provider for diabetes management and prevention. Patients who smoke need to be given resources to quit smoking."}
{"id": "article-26562_22", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Pearls and Other Issues", "content": "Patients\u00a0should undergo follow-up surveillance every 6 months for a year after the surgery with CT scans of the abdomen. If by 1 year nothing is seen, then patients can follow up annually and have imaging with MRCP to reduce radiation exposure.", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Pearls and Other Issues. Patients\u00a0should undergo follow-up surveillance every 6 months for a year after the surgery with CT scans of the abdomen. If by 1 year nothing is seen, then patients can follow up annually and have imaging with MRCP to reduce radiation exposure."}
{"id": "article-26562_23", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Enhancing Healthcare Team Outcomes", "content": "Management of IPMNs requires an interprofessional\u00a0team consisting of an oncology\u00a0nurse, oncologist, surgeon, and pharmacist specializing in oncologic medications. The patient will require regular follow-ups by the team for best results. [Level 5]", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Enhancing Healthcare Team Outcomes. Management of IPMNs requires an interprofessional\u00a0team consisting of an oncology\u00a0nurse, oncologist, surgeon, and pharmacist specializing in oncologic medications. The patient will require regular follow-ups by the team for best results. [Level 5]"}
{"id": "article-26562_24", "title": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Intraductal Papillary Mucinous Neoplasm of the Pancreas -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}